公开(公告)号：WO2010132471A2

公开(公告)日：2010-11-18

申请号：PCT/US2010034411

申请日：2010-05-11

Applicant: STC UNM ,  LOPEZ GABRIEL ,  CARROLL NICK ,  CUSHING KEVIN ,  PETSEV DIMITER N

Inventor： LOPEZ GABRIEL ,  CARROLL NICK ,  CUSHING KEVIN ,  PETSEV DIMITER N

IPC: A61K9/14 ,  A61K9/16 ,  A61K47/30 ,  A61K49/00

CPC classification number: C08L83/04 ,  A61K9/0009 ,  A61K9/1641 ,  A61K9/1682 ,  A61K47/34 ,  A61K49/225 ,  G01N33/538 ,  G01N33/54313

Abstract: We describe methods for synthesis and formulations of stable elastomeric negative acoustic contrast particles with controllable compressibility and density. These elastomeric negative acoustic contrast particles have a density/compressibility ratio that is less than that of water and therefore exhibit negative acoustic contrast under acoustic radiation exposure. This negative acoustic contrast allows our elastomeric negative acoustic contrast particles to be acoustically manipulated (e.g. separated) differently from other components (e.g. cells) within an aqueous solution. This disclosure also describes methods for biofunctionalization of the elastomeric negative acoustic contrast particles and as an example their use as platforms for bioassays. Potential applications of these elastomeric negative acoustic contrast particles include sensitive bioassays based on acoustic flow cytometry and other types of techniques that utilize acoustic fields, including ultrasound imaging and ultrasound triggered drug delivery.

Abstract translation: 我们描述了具有可压缩性和密度的稳定的弹性体负声学对比粒子的合成方法和配方。 这些弹性体负声学对比颗粒的密度/压缩比小于水的密度/压缩比，因此在声辐射暴露下呈现负的声学对比度。 这种负声学对比度允许我们的弹性体负声学对比粒子与水溶液中的其它组分（例如细胞）不同地被声学操纵（例如分离）。 本公开还描述了弹性体负声学对比粒子的生物功能化的方法，并且作为其用作生物测定平台的实例。 这些弹性体负声学对比粒子的潜在应用包括基于声流式细胞术的敏感生物测定和利用声场的其他类型的技术，包括超声成像和超声触发药物递送。

公开(公告)号：WO2010078569A3

公开(公告)日：2010-11-18

申请号：PCT/US2010020096

申请日：2010-01-05

Applicant: STC UNM ,  LIU JUEWEN ,  BRINKER C JEFFREY ,  ASHLEY CARLEE

Inventor： LIU JUEWEN ,  BRINKER C JEFFREY ,  ASHLEY CARLEE

IPC: A61K9/20 ,  A61K9/127 ,  A61K9/22 ,  B82B1/00 ,  B82B3/00

CPC classification number: A61K9/127 ,  A61K9/1272 ,  A61K9/5115 ,  A61K9/5123 ,  A61K31/713 ,  A61K33/00 ,  A61K33/06 ,  A61K33/24 ,  A61K38/16 ,  A61K39/3955 ,  A61K49/005

Abstract: Various exemplary embodiments provide protocell nanostructures and methods for constructing and using the protocell nanostructures. In one embodiment, the protocell nanostructures can include a core-shell structure including a porous particle core surrounded by a shell of lipid bilayer(s). The protocell can be internalized in a bioactive cell. Various cargo components, for example, drugs, can be loaded in and released from the porous particle core of the protocell(s) and then delivered within the bioactive cell.

Abstract translation: 各种示例性实施例提供了用于构建和使用原始细胞纳米结构的原始细胞纳米结构和方法。 在一个实施方案中，原始细胞纳米结构可以包括核 - 壳结构，该核 - 壳结构包括被脂质双层壳包围的多孔颗粒核心。 原始细胞可以内化于生物活性细胞中。 各种货物组分，例如药物，可以装入原始细胞的多孔颗粒核心并从其释放，然后在生物活性细胞内递送。

公开(公告)号：WO2009158606A3

公开(公告)日：2010-06-17

申请号：PCT/US2009048838

申请日：2009-06-26

Applicant: STC UNM ,  WHITTEN DAVID ,  TANG YANLI ,  ZHOU ZHIJUN ,  ISTA LINNEA ,  OGAWA MOTOKATSU ,  KELLER DAVID ,  ANDREZEJEWSKI BRETT ,  LOPEZ GABRIEL ,  SCHANZE KIRK

Inventor： WHITTEN DAVID ,  TANG YANLI ,  ZHOU ZHIJUN ,  ISTA LINNEA ,  OGAWA MOTOKATSU ,  KELLER DAVID ,  ANDREZEJEWSKI BRETT ,  LOPEZ GABRIEL ,  SCHANZE KIRK

IPC: C07C211/63 ,  A01N33/06 ,  A01N33/12 ,  C07C69/76 ,  C12M1/00 ,  C12Q1/00 ,  G01N27/00

CPC classification number: C07C217/20 ,  A01N33/12 ,  A01N37/38

Abstract: Novel compounds generally referred to herein as cationic oligomeric phenylene ethynylenes (OPEs), methods of synthesizing OPEs and various uses for the OPEs are described. The compounds can be synthesized in both symmetrical (S-OPE) and non- symmetrical (N-OPE) forms. Suitable uses include sensor and biocidal applications. Reusable structures incorporating the OPEs that are able to capture and release biological species of interest are also described.

Abstract translation: 本文中通常称为阳离子低聚亚苯基乙烯基（OPE）的新型化合物，OPE的合成方法和OPE的各种用途。 这些化合物可以以对称（S-OPE）和非对称（N-OPE）形式合成。 合适的用途包括传感器和杀菌剂应用。 还描述了结合能够捕获和释放感兴趣的生物物种的OPE的可再利用结构。

公开(公告)号：WO2010002859A3

公开(公告)日：2010-05-14

申请号：PCT/US2009049208

申请日：2009-06-30

Applicant: STC UNM ,  KISSEL DAVID J ,  BRINKER CHARLES JEFFREY

Inventor： KISSEL DAVID J ,  BRINKER CHARLES JEFFREY

IPC: C09D183/02 ,  C09D5/00 ,  C09K3/18

CPC classification number: C09D183/02 ,  C08K3/36 ,  C08K7/26 ,  C08K9/06 ,  C09D5/14 ,  C09D5/1687 ,  C09D7/1225 ,  C09D7/62 ,  C09K3/18 ,  Y10T428/24975 ,  Y10T428/249953 ,  Y10T428/249981 ,  Y10T428/249986 ,  Y10T428/24999 ,  Y10T428/249991 ,  Y10T442/20 ,  Y10T442/218 ,  Y10T442/2279 ,  Y10T442/2525 ,  Y10T442/259

Abstract: Provided are superhydrophobic coatings, devices and articles including superhydrophobic coatings, and methods for preparing the superhydrophobic coatings. The exemplary superhydrophobic device can include a substrate component and one or more superhydrophobic coatings disposed over the substrate component, wherein at least one of the one or more superhydrophobic coatings has a water contact angle of at least about 150° and a contact angle hysteresis of less than about 1°. The one or more superhydrophobic coatings can include an ultra high water content acid catalyzed polysilicate gel, the polysilicate gel including a three dimensional network of silica particles having surface functional groups derivatized with a silylating agent and a plurality of pores.

Abstract translation: 提供了超疏水涂层，包括超疏水涂层的装置和制品，以及制备超疏水涂层的方法。 示例性的超疏水性装置可以包括基体组分和设置在基体组件上的一个或多个超疏水性涂层，其中所述一种或多种超疏水性涂层中的至少一个具有至少约150°的水接触角和较小的接触角滞后 大约1°。 所述一种或多种超疏水涂层可包含超高含水量酸催化聚硅酸盐凝胶，所述聚硅酸盐凝胶包含具有用甲硅烷基化试剂衍生的表面官能团和多个孔隙的二氧化硅颗粒的三维网络。

公开(公告)号：WO2010014827A3

公开(公告)日：2010-04-29

申请号：PCT/US2009052277

申请日：2009-07-30

Applicant: STC UNM ,  SMYTH HUGH D C ,  DONOVAN MARTIN

Inventor： SMYTH HUGH D C ,  DONOVAN MARTIN

IPC: A61K9/14

CPC classification number: A61K9/0075 ,  Y10T428/2982

Abstract: A dry powder inhaler may include a drug chamber configured to contain a formulation including carrier particles and working agent particles, a mouthpiece configured to direct flow of working agent particles to a user, and a retaining member proximal the mouthpiece. The retaining member be sized and arranged to prevent flow of substantially all carrier particles to the user while permitting flow of working agent particles to a user. The inhaler may include a formulation including carrier particles for delivering working agent to the pulmonary system of a patient. The carrier particles may have an average sieve diameter greater than about 500 µm. The carrier particles may be one of polystyrene, PTFE, silicone glass, and silica gel or glass.

Abstract translation: 干粉吸入器可以包括药物腔室，该药物腔室构造成容纳包括载体颗粒和工作剂颗粒的制剂，构造成引导工作剂颗粒流向使用者的嘴部和靠近嘴部件的保持构件。 保持构件的尺寸和布置被设置成防止基本上所有载体颗粒流向使用者，同时允许工作剂颗粒流向使用者。 吸入器可以包括含有载体颗粒的制剂，用于将工作剂递送至患者的肺部系统。 载体颗粒可具有大于约500μm的平均筛直径。 载体颗粒可以是聚苯乙烯，PTFE，硅酮玻璃，硅胶或玻璃中的一种。

公开(公告)号：WO2009148566A3

公开(公告)日：2010-02-25

申请号：PCT/US2009003338

申请日：2009-06-02

Applicant: STC UNM ,  DU CLOS TERRY W ,  MOLD CAROLYN

Inventor： DU CLOS TERRY W ,  MOLD CAROLYN

IPC: A61K38/16 ,  A61P13/12 ,  A61P19/02

CPC classification number: A61K38/1745 ,  C07K14/4737

Abstract: The present invention relates to the use of a mutant CRP molecule in which tyrosine 175 is replaced by leucine (Y175L CRP) or the leucine 176 is replaced by glutamic acid (L176E CRP) for the treatment of various disease states and conditions associated with SLE, including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with SLE will have an outbreak is an additional aspect of the present invention. The present invention relates to the use of mutant Y175L CRP or L176E CRP in the treatment of a number of disease states or conditions that occur secondary to systemic lupus SLE. The present invention also relates to the treatment of immune thrombocytopenic purpura. Pharmaceutical compositions are also disclosed based these mutant CRP molecules.

Abstract translation: 本发明涉及使用由亮氨酸（Y175L CRP）代替酪氨酸175或用谷氨酸（L176E CRP）代替的亮氨酸176用于治疗与SLE有关的各种疾病状态和病症的突变型CRP分子， 包括皮肤（盘状）的狼疮，关节，肺和肾的系统性红斑狼疮，包括溶血性贫血和低淋巴细胞计数的血液学病症，淋巴结病和CNS作用，包括记忆丧失，癫痫发作和精神病，其他如本文另有公开。 在本发明的另一方面，降低与SLE相关的疾病状态或病症发生风险的患者将发生爆发的可能性是本发明的另外的方面。 本发明涉及突变型Y175L CRP或L176E CRP在治疗多发于系统性红斑狼疮SLE继发性疾病状态或病症中的应用。 本发明还涉及免疫性血小板减少性紫癜的治疗。 还公开了基于这些突变型CRP分子的药物组合物。

公开(公告)号：WO2009151646A2

公开(公告)日：2009-12-17

申请号：PCT/US2009003569

申请日：2009-06-15

Applicant: STC UNM ,  NORENBERG JEFFREY P

Inventor： NORENBERG JEFFREY P

IPC: A61K51/00 ,  A61K31/4178 ,  A61K103/20 ,  A61K103/34 ,  A61P31/00 ,  A61P31/04

CPC classification number: A61K51/0453 ,  A61K31/4178 ,  A61K51/00 ,  A61K51/044 ,  A61K51/0497 ,  G01N33/569 ,  G01N2333/70525 ,  G01N2333/70553

Abstract: The present invention is directed to novel non-invasive diagnostic tools to diagnose numerous infectious disease states or conditions. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these disease states. The novel imaging probe is capable of detecting infected cells, as well tissue. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to therapeutic treatments and other interventions or therapies used in the treatment of these disease states or conditions. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states. Pharmaceutical compositions are also described.

Abstract translation: 本发明涉及用于诊断许多传染病状态或病症的新型非侵入性诊断工具。 本发明代表了本领域的显着进步，其目前依赖于组织活检以诊断这些疾病状态。 该新型成像探针能够检测感染的细胞以及组织。 这代表了使用非侵入性分子成像技术在NHL的诊断和分期中向前推进的量子进程。 这种新型探针也可用于监测患者治疗治疗和治疗这些疾病状态或病症的其他干预措施或疗法的反应。 根据本发明的化合物可以用作许多病症和疾病状态的诊断工具以及用于治疗这些病症和疾病状态的治疗剂。 还描述了药物组合物。

公开(公告)号：WO2009128961A3

公开(公告)日：2009-12-10

申请号：PCT/US2009031110

申请日：2009-01-15

Applicant: STC UNM ,  EPSTEIN RICHARD I ,  MALLOY KEVIN J ,  SHEIK-BAHAE MANSOOR

Inventor： EPSTEIN RICHARD I ,  MALLOY KEVIN J ,  SHEIK-BAHAE MANSOOR

IPC: G05D23/00 ,  H01H37/00 ,  H01L39/00

CPC classification number: F28F13/16 ,  F28F2013/008

Abstract: In accordance with the invention, there are thermal switches, method of operating thermal switches and methods of forming thermal switches. A thermal switch can include a thin layer of liquid crystal disposed between a first surface of a first insulating substrate and a second surface of a second insulating substrate, wherein the liquid crystals are aligned at one or more of the first surface and the second surface due to surface preparation.

Abstract translation: 根据本发明，存在热开关，操作热开关的方法和形成热开关的方法。 热开关可以包括设置在第一绝缘基板的第一表面和第二绝缘基板的第二表面之间的液晶薄层，其中液晶在第一表面和第二表面的一个或多个处被排列，因为 进行表面处理。

公开(公告)号：WO2008060949A2

公开(公告)日：2008-05-22

申请号：PCT/US2007084122

申请日：2007-11-08

Applicant: STC UNM ,  THOMPSON TODD A ,  MACKENZIE DEBRA A

Inventor： THOMPSON TODD A ,  MACKENZIE DEBRA A

IPC: A61K31/277 ,  A61K31/095 ,  A61K31/12 ,  A61K31/13 ,  A61K31/135 ,  A61K31/165 ,  A61K31/185

CPC classification number: A61K31/095 ,  A61K31/12 ,  A61K31/13 ,  A61K31/135 ,  A61K31/165 ,  A61K31/185 ,  A61K31/277

Abstract: Compounds having anti-androgenic activities are disclosed. Further disclosed are methods of using the compounds to prevent or treat androgen-dependent diseases or to provide nutraceutical benefits. Pharmaceutical and nutraceutical compositions containing the anti-androgenic compounds are also disclosed.

Abstract translation: 公开了具有抗雄激素活性的化合物。 还公开了使用所述化合物预防或治疗雄激素依赖性疾病或提供营养保健益处的方法。 还公开了含有抗雄激素化合物的药物和营养制品组合物。

公开(公告)号：WO2008008383A9

公开(公告)日：2008-03-27

申请号：PCT/US2007015802

申请日：2007-07-11

Applicant: STC UNM ,  TIMMINS GRAHAM S

Inventor： TIMMINS GRAHAM S

IPC: C12Q1/00

CPC classification number: A61K49/0008 ,  A61B5/0059 ,  A61B5/444 ,  A61B5/445 ,  G01R33/60

Abstract: The present invention is a system and methods of establishing a Melanocyte Protection Factor (MPF), which indicates the level of protection against DNA damage to a target cell, such as the level of protection a particular sunscreen offers against UVA rays when compared to the unprotected case, i.e., no sunscreen. The present invention determines and records levels of stable melanin radicals (SMR) in a target cell. Light is applied to the target cell forming light-induced melanin radicals (LIR). The levels of SMR and intensity of LIR are measured to determine the amount of incident light reaching the target cell. Since LIR is proportional to the square root of light intensity reaching the target cell, the ratio of light reaching the target cell is defined as the MPF (I).

Abstract translation: 本发明是建立黑素细胞保护因子（MPF）的系统和方法，其表明针对靶细胞的DNA损伤的保护水平，例如与未受保护的相比，特定防晒剂针对UVA射线提供的保护水平 案例，即没有防晒霜。 本发明确定并记录靶细胞中稳定的黑色素自由基（SMR）的水平。 光照射到靶细胞形成光诱导黑素自由基（LIR）。 测量SMR的水平和LIR的强度以确定到达目标细胞的入射光的量。 由于LIR与到达目标细胞的光强度的平方根成比例，所以到达目标细胞的光的比率被定义为MPF（I）。